Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Complete remission following chemotherapy with low-dose cytosine arabinoside and macrophage colony-stimulating factor/granulocyte colony-stimulating factor in a patient with relapsed acute myeloid leukemia after stem cell transplantation.

Okada K, Higashiyama A, Takahata M, Onozawa M, Kahata K, Ando S, Tanaka J, Hashino S, Imamura M.

Intern Med. 2012;51(20):2937-41. Epub 2012 Oct 15.

PMID:
23064572
[PubMed - indexed for MEDLINE]
Free Article
2.

FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.

Eom KS, Min WS, Kim HJ, Cho BS, Choi SM, Lee DG, Lee S, Min CK, Kim YJ, Cho SG, Lee JW, Kim CC.

Med Oncol. 2011 Dec;28 Suppl 1:S462-70. doi: 10.1007/s12032-010-9653-6. Epub 2010 Aug 17.

PMID:
20714942
[PubMed - indexed for MEDLINE]
3.
4.

Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.

Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q.

Leuk Lymphoma. 2009 Sep;50(9):1461-7. doi: 10.1080/10428190903096719.

PMID:
19672772
[PubMed - indexed for MEDLINE]
5.

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.

PMID:
17339189
[PubMed - indexed for MEDLINE]
Free Article
6.

[Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].

Zhu BG, Qian SX, Hong M, Lu H, Wu HX, Zhang SJ, Qiu HX, Xu W, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):760-4. Chinese.

PMID:
19549403
[PubMed - indexed for MEDLINE]
7.

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.

Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A; Polish Adult Leukemia Group.

Eur J Haematol. 2008 Feb;80(2):115-26. Epub 2007 Dec 11.

PMID:
18076637
[PubMed - indexed for MEDLINE]
8.
9.

Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.

Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, Wang JL.

Am J Hematol. 2008 Mar;83(3):185-8.

PMID:
17899614
[PubMed - indexed for MEDLINE]
10.

FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.

Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.

Ann Hematol. 2003 Apr;82(4):231-5. Epub 2003 Mar 15.

PMID:
12707726
[PubMed - indexed for MEDLINE]
11.

[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].

Saito K, Furusawa S, Yamada K, Waga K, Aoyagi A, Koike T, Arimura H, Noguchi M, Yamato H, Sakuma H, et al.

Rinsho Ketsueki. 1995 Mar;36(3):165-74. Japanese.

PMID:
7540220
[PubMed - indexed for MEDLINE]
12.
13.

Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.

Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD.

Leukemia. 1991 Mar;5(3):230-8.

PMID:
1826536
[PubMed - indexed for MEDLINE]
14.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.

PMID:
18571721
[PubMed - indexed for MEDLINE]
15.

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.

Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.

Biol Blood Marrow Transplant. 2008 Jun;14(6):651-7. doi: 10.1016/j.bbmt.2008.03.006.

PMID:
18489990
[PubMed - indexed for MEDLINE]
16.

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.

Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S; Polish Adult Leukemia Group.

Ann Hematol. 2005 Sep;84(9):557-64. Epub 2005 Apr 27.

PMID:
15856358
[PubMed - indexed for MEDLINE]
17.

Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.

Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F.

Onkologie. 2001 Aug;24(4):356-60.

PMID:
11574763
[PubMed - indexed for MEDLINE]
18.

Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.

Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, Nakamura Y, Arai Y, Tadokoro J, Handa T, Tsurumi S, Arai H, Kawagoe Y, Gunnji H, Kitsukawa Y, Takahashi W, Furusawa S.

Int J Hematol. 2000 Apr;71(3):238-44.

PMID:
10846828
[PubMed - indexed for MEDLINE]
19.

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.

Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.

Turk J Pediatr. 2000 Jul-Sep;42(3):198-204.

PMID:
11105617
[PubMed - indexed for MEDLINE]
20.

[Trial of combined cytosine arabinoside with granulocyte colony-stimulating factor therapy or refractory acute myeloid leukemia].

Mori H, Kuriyama K, Tawara M, Danno Y, Fujimoto K, Tushima H, Saito M, Yamamura M, Hata T, Arimura M, et al.

Rinsho Ketsueki. 1995 Jul;36(7):648-56. Japanese.

PMID:
7563592
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk